<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475020</article-id><article-id pub-id-type="pmcid-ver">PMC12475020.1</article-id><article-id pub-id-type="pmcaid">12475020</article-id><article-id pub-id-type="pmcaiid">12475020</article-id><article-id pub-id-type="pmid">41006510</article-id><article-id pub-id-type="doi">10.1038/s41598-025-17641-7</article-id><article-id pub-id-type="publisher-id">17641</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cathepsin B in human peripheral blood lymphocytes as a peripheral biomarker for cardiac hypertrophy</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Feng</surname><given-names initials="D">Dandan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="C">Chao</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="W">Wenjuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sui</surname><given-names initials="Y">Yuying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="S">Shuxin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yixing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="G">Guoying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Dong</surname><given-names initials="Y">Yan</given-names></name><address><email>dongyansy@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jianchun</given-names></name><address><email>wangjianchun@sdfmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02ar2nf05</institution-id><institution-id institution-id-type="GRID">grid.460018.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1769 9639</institution-id><institution>Department of Geriatrics, </institution><institution>Shandong Provincial Hospital, Shandong First Medical University, </institution></institution-wrap>Jinan, 250021 Shandong China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02ar2nf05</institution-id><institution-id institution-id-type="GRID">grid.460018.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1769 9639</institution-id><institution>Department of Anesthesia and Surgery, </institution><institution>Shandong Provincial Hospital, Shandong First Medical University, </institution></institution-wrap>Jinan, 250021 Shandong China </aff><aff id="Aff3"><label>3</label>Shandong Provincial Clinical Research Center for Geriatric Diseases, Jinan, 250021 Shandong China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>32980</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 16:25:18.507"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_17641.pdf"/><abstract id="Abs1"><p id="Par8">Previous studies have demonstrated that cathepsin B is up-regulated in the myocardium of both mice and humans with pathological cardiac hypertrophy. However, it remains unknown whether cathepsin B is detectable in human peripheral blood lymphocytes (PBLs) and whether its expression is associated with pathological hypertrophy. In this study, immunofluorescence staining confirmed the presence of cathepsin B in human PBLs. Western blotting analysis and correlation studies further revealed a positive correlation between cathepsin B protein levels in PBLs and that in cardiac tissues (<italic toggle="yes">r</italic>&#8201;=&#8201;0.441, <italic toggle="yes">p</italic>&#8201;=&#8201;0.017). We also investigated the association between cathepsin B expression level in PBLs and cardiac structure and function. Quantitative PCR and western blotting analyses indicated that patients with left ventricular hypertrophy, particularly those with eccentric hypertrophy, exhibited significantly elevated cathepsin B expression in PBLs (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Logistic regression analysis identified cathepsin B as an independent risk factor for left ventricular hypertrophy (odds ratio&#8201;=&#8201;4.863, 95% confidence interval: 1.341&#8211;17.632). Receiver operating characteristic analysis further supported its diagnostic value (area under the curve&#8201;=&#8201;0.748, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001). In summary, cathepsin B levels in PBLs positively correlates with myocardial levels and may serve as a peripheral biomarker for diagnosing maladaptive cardiac hypertrophy.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-17641-7.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Pathological cardiac hypertrophy</kwd><kwd>Cathepsin B</kwd><kwd>Human peripheral blood lymphocytes</kwd><kwd>Biomarker</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Biomarkers</kwd><kwd>Cardiology</kwd><kwd>Diseases</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Key Research and Development Program of China</institution></funding-source><award-id>2020YFC2008900</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Jianchun</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par37">Pathological cardiac hypertrophy is typically a precursor to heart failure and is characterized by an increase in cardiomyocyte size and thickening of the ventricular wall in response to increased workload or cardiac insult<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Although this hypertrophic response is initially adaptive and compensatory, prolonged exposure to stress can result in ventricular dilation, cardiac dysfunction, and ultimately heart failure<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. Despite significant progress has been made in elucidating the underlying mechanisms of pathological cardiac hypertrophy, effective measures for assessing the progression of myocardial hypertrophy remain limited<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par38">Cathepsin B is a lysosomal cysteine protease that was originally synthesized as a precursor form in the endoplasmic reticulum and contains a signal peptide and a propeptide. The signal peptide guides the precursor into the endoplasmic reticulum cavity and is excised to form enzymegen. Enzymogen is modified in the Golgi apparatus and transported to lysosomes via the M6P receptor-mediated pathway. In the acidic environment of lysosomes, the propeptide is excised, generating a mature single-chain form (~&#8201;30&#160;kDa). In some cases, the single-chain can be further hydrolyzed into double-stranded forms (a light chain&#8201;~&#8201;5&#8211;7&#160;kDa and a heavy chain&#8201;~&#8201;20&#8211;25&#160;kDa, linked by disulfide bonds)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Both the mature single-chain and double-chain forms have complete catalytic domains, and the active sites of the double-chain are fully exposed, so it have higher enzymatic activity than the single-chain<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Mature single-chain form is mainly localized in lysosomes, and a few can be secreted extracellularly to promote extracellular matrix remodeling<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Double-chain form is strictly localized in the lysosome, involved in physiological processes such as antigen presentation and autophagy-lysosomal degradation. Under pathological conditions, when the lysosomal membrane is damaged, it will infiltrate the cytoplasm and trigger cell apoptosis<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>.</p><p id="Par39">Recent studies have highlighted the role of dysregulated cathepsin B, in the development of pathological cardiac hypertrophy<sup><xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref></sup>. Studies using murine models have shown that both the expression and activity of cathepsin B are elevated in hypertrophic myocardial tissue induced by angiotensin II and pressure overload. Moreover, cathepsin B knockout has been shown to attenuate pathological hypertrophy<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref></sup>. Elevated cathepsin B expression has also been observed in the myocardium of patients with dilated and hypertrophic cardiomyopathy<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. Our previous work demonstrated a significant correlation between calcineurin expression in human peripheral blood lymphocytes (PBLs) and that in myocardial tissue in patients with valvular atrial fibrillation or heart failure<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. Although upregulation of cathepsin B in myocardial tissue is well-documented in both animal models and human cardiac hypertrophy, its expression in PBLs and its clinical significance have not yet been investigated. In this study, we aimed to investigate the association between cathepsin B expression in PBLs and pathological cardiac hypertrophy.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Expression of cathepsin B in human PBLs</title><p id="Par40">Immunofluorescence staining confirmed the localization of cathepsin B in PBLs (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A). The protein levels of cathepsin B in PBLs and left atrial appendage tissues from 30 patients were assessed using western blotting analysis. As illustrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B, The protein bands of cathepsin B in myocardial tissues were mainly distributed at the 25&#160;kDa level, and the majority of cathepsin B protein in PBLs was presented at the 30&#160;kDa level. Thus, we speculate that the cathepsin B in myocardial tissues mostly exist in double-chain form, while the protein in PBLs mainly exist in mature single-chain form. Furthermore, the correlation between cathepsin B protein levels in PBLs and those in myocardial tissue was analyzed, and a significant positive correlation was observed between them (<italic toggle="yes">r</italic>&#8201;=&#8201;0.441, <italic toggle="yes">p</italic>&#8201;=&#8201;0.017). Therefore, the expression of cathepsin B in PBLs may reflect its levels in myocardial tissue to a certain extent.</p><p id="Par41">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Expression of cathepsin B (CTSB) in human PBLs. (<bold>A</bold>) Immunofluorescence staining deteced the cathepsin B expression in human PBLs. No-primary control refers to the condition without primary antibody incubation. Scale bar =&#8201;10&#160;&#956;m. (<bold>B</bold>) Cathepsin B protein expession in both PBLs and in left atrial appendage tissues from 30 patients were assessed using western blotting analysis. Original blots are presented in Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>. Cathepsin B protein levels were calculated by the ratio of the gray value of its protein band to the gray value of tubulin. Spearman correlation was used to analyze the correlation between the protein levels of cathepsin B in PBLs and that in myocardial tissues. The shaded area represent 95% confidence bands.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e481" position="float" orientation="portrait" xlink:href="41598_2025_17641_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>Comparison of the baseline data of the subjects</title><p id="Par42">As summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, significant differences were noted between the non-left ventricular hypertrophy (non-LVH) and LVH groups in terms of age, body mass index (BMI), NT-proBNP, serum creatinine, and histories of hypertension and atrial fibrillation. Specifically, the LVH group exhibited higher NT-proBNP and serum creatinine levels, as well as a longer history of hypertension compared to the non-LVH group. Furthermore, echocardiographic parameters, including left atrial diameter (LAD), left ventricular end-diastolic dimension (LVDD), interventricular septal thickness (IVST), and left ventricular posterior wall thickness (LVPWT), were significantly higher in the LVH group than in the non-LVH group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), whereas the left ventricular ejection fraction (LVEF) was significantly lower (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Additionally, age, BMI, NT-proBNP, serum creatinine, history of atrial fibrillation, and echocardiographic indices showed statistically significant differences among groups with varying left ventricular geometrical configuration groups (see Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>). Other indicators did not differ significantly.</p><p id="Par43">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Comparison of the basic data of the LVH group and non-LVH group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Indexes</th><th align="left" colspan="1" rowspan="1">Non-LVH (<italic toggle="yes">n</italic>&#8201;=&#8201;153)</th><th align="left" colspan="1" rowspan="1">LVH (<italic toggle="yes">n</italic>&#8201;=&#8201;72)</th><th align="left" colspan="1" rowspan="1">t/z/&#967;<sup>2</sup></th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (<inline-formula id="IEq1"><alternatives><tex-math id="d33e543">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\stackrel{-}{x}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq1.gif"/></alternatives></inline-formula>&#177;<italic toggle="yes">&#3923;</italic>, years)</td><td align="left" colspan="1" rowspan="1">63.78&#8201;&#177;&#8201;1.20</td><td align="left" colspan="1" rowspan="1">69.81&#8201;&#177;&#8201;1.57</td><td char="." align="char" colspan="1" rowspan="1">2.924</td><td char="." align="char" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender [<italic toggle="yes">n</italic> (%)]</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.028</td><td char="." align="char" colspan="1" rowspan="1">0.868</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">96 (62.75)</td><td align="left" colspan="1" rowspan="1">46 (63.89)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">57 (37.25)</td><td align="left" colspan="1" rowspan="1">26 (36.11)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BMI [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), kg/<inline-formula id="IEq2"><alternatives><tex-math id="d33e601">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\text{m}}^{2}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq2.gif"/></alternatives></inline-formula>]</td><td align="left" colspan="1" rowspan="1">25.56 (4.89)</td><td align="left" colspan="1" rowspan="1">24.67 (3.93)</td><td char="." align="char" colspan="1" rowspan="1">2.157</td><td char="." align="char" colspan="1" rowspan="1">0.031</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking index [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>)]</td><td align="left" colspan="1" rowspan="1">0.00 (200.00)</td><td align="left" colspan="1" rowspan="1">0.00 (60.00)</td><td char="." align="char" colspan="1" rowspan="1">0.606</td><td char="." align="char" colspan="1" rowspan="1">0.545</td></tr><tr><td align="left" colspan="1" rowspan="1">Drinking index [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>)]</td><td align="left" colspan="1" rowspan="1">0.00 (1000.00)</td><td align="left" colspan="1" rowspan="1">0.00 (0.00)</td><td char="." align="char" colspan="1" rowspan="1">1.062</td><td char="." align="char" colspan="1" rowspan="1">0.288</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), years]</td><td align="left" colspan="1" rowspan="1">1.00(10.00)</td><td align="left" colspan="1" rowspan="1">7.50 (13.00)</td><td char="." align="char" colspan="1" rowspan="1">2.460</td><td char="." align="char" colspan="1" rowspan="1">0.014</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), years]</td><td align="left" colspan="1" rowspan="1">0.00(3.50)</td><td align="left" colspan="1" rowspan="1">0.00(6.00)</td><td char="." align="char" colspan="1" rowspan="1">0.408</td><td char="." align="char" colspan="1" rowspan="1">0.683</td></tr><tr><td align="left" colspan="1" rowspan="1">CAD [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), years]</td><td align="left" colspan="1" rowspan="1">0.00 (4.00)</td><td align="left" colspan="1" rowspan="1">0.00 (8.00)</td><td char="." align="char" colspan="1" rowspan="1">0.727</td><td char="." align="char" colspan="1" rowspan="1">0.467</td></tr><tr><td align="left" colspan="1" rowspan="1">AF [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), years]</td><td align="left" colspan="1" rowspan="1">0.00 (0.00)</td><td align="left" colspan="1" rowspan="1">0.00 (1.00)</td><td char="." align="char" colspan="1" rowspan="1">3.528</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">NT-proBNP [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), pg/L]</td><td align="left" colspan="1" rowspan="1">188.85 (527.38)</td><td align="left" colspan="1" rowspan="1">539.50 (1777.45)</td><td char="." align="char" colspan="1" rowspan="1">3.439</td><td char="." align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Fasting blood glucose</p><p>[<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), mmol/L]</p></td><td align="left" colspan="1" rowspan="1">5.83 (1.85)</td><td align="left" colspan="1" rowspan="1">6.02 (2.16)</td><td char="." align="char" colspan="1" rowspan="1">0.223</td><td char="." align="char" colspan="1" rowspan="1">0.823</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Serum creatinine</p><p>[<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), &#181;mol/L]</p></td><td align="left" colspan="1" rowspan="1">61.70 (21.85)</td><td align="left" colspan="1" rowspan="1">69.7 (26.50)</td><td char="." align="char" colspan="1" rowspan="1">3.602</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL-C [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), mmol/L]</td><td align="left" colspan="1" rowspan="1">2.43 (1.35)</td><td align="left" colspan="1" rowspan="1">2.38 (1.13)</td><td char="." align="char" colspan="1" rowspan="1">0.742</td><td char="." align="char" colspan="1" rowspan="1">0.458</td></tr><tr><td align="left" colspan="1" rowspan="1">TG [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), mmol/L]</td><td align="left" colspan="1" rowspan="1">1.30 (0.90)</td><td align="left" colspan="1" rowspan="1">1.13 (0.64)</td><td char="." align="char" colspan="1" rowspan="1">1.024</td><td char="." align="char" colspan="1" rowspan="1">0.306</td></tr><tr><td align="left" colspan="1" rowspan="1">TC [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), mmol/L]</td><td align="left" colspan="1" rowspan="1">4.06 (1.78)</td><td align="left" colspan="1" rowspan="1">3.98 (1.42)</td><td char="." align="char" colspan="1" rowspan="1">0.831</td><td char="." align="char" colspan="1" rowspan="1">0.406</td></tr><tr><td align="left" colspan="1" rowspan="1">LAD [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), cm]</td><td align="left" colspan="1" rowspan="1">3.69 (0.75)</td><td align="left" colspan="1" rowspan="1">4.24 (1.08)</td><td char="." align="char" colspan="1" rowspan="1">5.817</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">LVDD [<inline-formula id="IEq3"><alternatives><tex-math id="d33e856">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\stackrel{-}{x}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq1.gif"/></alternatives></inline-formula>&#177;<italic toggle="yes">S</italic>, cm]</td><td align="left" colspan="1" rowspan="1">4.60&#8201;&#177;&#8201;0.03</td><td align="left" colspan="1" rowspan="1">5.33&#8201;&#177;&#8201;0.08</td><td char="." align="char" colspan="1" rowspan="1">10.387</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">IVST [<inline-formula id="IEq4"><alternatives><tex-math id="d33e877">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\stackrel{-}{x}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq1.gif"/></alternatives></inline-formula>&#177;<italic toggle="yes">S</italic>, cm]</td><td align="left" colspan="1" rowspan="1">0.94&#8201;&#177;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">1.06&#8201;&#177;&#8201;0.02</td><td char="." align="char" colspan="1" rowspan="1">7.889</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">LVPWT [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), cm]</td><td align="left" colspan="1" rowspan="1">0.93 (0.01)</td><td align="left" colspan="1" rowspan="1">1.04 (0.02)</td><td char="." align="char" colspan="1" rowspan="1">5.710</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">LVEF [<italic toggle="yes">M</italic> (<italic toggle="yes">IQR</italic>), %]</td><td align="left" colspan="1" rowspan="1">60.00 (3.00)</td><td align="left" colspan="1" rowspan="1">57.50 (7.00)</td><td char="." align="char" colspan="1" rowspan="1">5.715</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">M</italic> Median, <italic toggle="yes">IQR</italic> Interquartile range, <italic toggle="yes">CAD</italic> Coronary atherosclerotic heart disease, <italic toggle="yes">AF</italic> Atrial fibrillation, <italic toggle="yes">LDL-C</italic> Low density lipoprotein cholesterol, <italic toggle="yes">HDL-C</italic> High density lipoprotein cholesterol, <italic toggle="yes">TG</italic> Triglyceride, <italic toggle="yes">TC</italic> serum total cholesterol, <italic toggle="yes">LAD</italic> Left atrial diameter, <italic toggle="yes">LVDD</italic> Left ventricular end-diastolic dimension, <italic toggle="yes">IVST</italic> Interventricular septal thickness, <italic toggle="yes">LVPWT</italic> Left ventricular posterior wall thickness, <italic toggle="yes">LVEF</italic> Left ventricular ejection fraction.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec5"><title>Comparison of cathepsin B expression in PBLs among different groups</title><p id="Par44">Quantitative PCR (qPCR) and western blotting analyses were conducted to compare cathepsin B expression in PBLs across different groups. As shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A, the qPCR results indicated that cathepsin B mRNA levels in PBLs were significantly higher in the LVH group than in the non-LVH group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.027). Similarly, western blotting analysis demonstrated a marked increase in cathepsin B protein levels in the LVH group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). Subgroup analysis based on left ventricular geometry revealed that both mRNA and protein levels of cathepsin B in PBLs were significantly elevated in the eccentric hypertrophy (EH) group compared to the normal geometry (NG), centripetal remodeling (CR), and centripetal hypertrophy (CH) groups (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C-D). Notably, no significant differences were observed between the CR and CH groups compared to the NG group. In summary, cathepsin B expression in PBLs was significantly upregulated in patients with LVH, particularly in those with EH.</p><p id="Par45">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Comparison of the expression of cathepsin B in PBLs. (<bold>A</bold>) The qPCR analysis of cathepsin B mRNA levels in PBLs among the non-LVH (<italic toggle="yes">n</italic>&#8201;=&#8201;60) and LVH (<italic toggle="yes">n</italic>&#8201;=&#8201;30) groups. (<bold>B</bold>)Western blotting analysis was used to detected the cathepsin B protein levels among the non-LVH (<italic toggle="yes">n</italic>&#8201;=&#8201;61) and LVH (<italic toggle="yes">n</italic>&#8201;=&#8201;28) groups. Original blots are presented in Supplementary Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. (<bold>C</bold>) The qPCR detected cathepsin B mRNA levels in PBLs of the NG (<italic toggle="yes">n</italic>&#8201;=&#8201;27), CR (27), CH (<italic toggle="yes">n</italic>&#8201;=&#8201;16), and EH (<italic toggle="yes">n</italic>&#8201;=&#8201;13) groups. (<bold>D</bold>) The cathepsin B protein levels in PBLs of the NG (<italic toggle="yes">n</italic>&#8201;=&#8201;39), CR (22), CH (<italic toggle="yes">n</italic>&#8201;=&#8201;11), and EH (<italic toggle="yes">n</italic>&#8201;=&#8201;17) groups. Annotation: CTSB, cathepsin B; NG, normal geometry; CR, centripetal remodeling; CH, centripetal hypertrophy; EH, eccentric hypertrophy; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01,***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1063" position="float" orientation="portrait" xlink:href="41598_2025_17641_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec6"><title>Diagnostic efficiency of cathepsin B in PBLs for LVH</title><p id="Par46">Binary logistic regression analyses were conducted to identify factors influencing LVH. Cathepsin B protein levels in PBLs and other clinical indices showing significant differences (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) were included in the univariate logistic regression analysis. Variables with statistical significance (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) were subsequently included in a multivariate logistic regression model to control potential confounders. As shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>, the results indicated that age, BMI, NT-proBNP, serum creatinine, and history of hypertension were significant factors for LVH (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Furthermore, cathepsin B protein levels in PBLs was identified as an independent risk factor for LVH (<italic toggle="yes">p</italic>&#8201;=&#8201;0.016, <italic toggle="yes">B</italic>&#8201;=&#8201;1.582, odds ratio [<italic toggle="yes">OR</italic>]&#8201;=&#8201;4.863, 95% confidence interval [<italic toggle="yes">CI</italic>]: 1.341&#8211;17.632). Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the diagnostic performance of cathepsin B protein levels in PBLs for LVH. As shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>, the area under the curve (AUC) was 0.748 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.001, 95% <italic toggle="yes">CI</italic>: 0.616&#8211;0.881), indicating moderate diagnostic efficacy. Furthermore, a polynomial logistic regression analysis was performed to identify factors influencing the progression of left ventricular geometry. Variables included cathepsin B protein levels in PBLs and other clinical indices that showed significant differences in baseline data (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). As shown in Supplementary Table <xref rid="Tab2" ref-type="table">2</xref>, cathepsin B protein levels significantly influenced the development of left ventricular configuration (<italic toggle="yes">p</italic>&#8201;=&#8201;0.002, <italic toggle="yes">B</italic>&#8201;=&#8201;1.665, <italic toggle="yes">OR</italic>&#8201;=&#8201;5.258, 95% <italic toggle="yes">CI</italic>: 1.831&#8211;15.253).</p><p id="Par47">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>The univariate and multivariate logistic regression analysis of LVH.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Items</th><th align="left" colspan="1" rowspan="1">B</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" colspan="1" rowspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Univariate</td><td align="left" colspan="1" rowspan="1">Age</td><td char="." align="char" colspan="1" rowspan="1">0.030</td><td char="." align="char" colspan="1" rowspan="1">0.010</td><td char="." align="char" colspan="1" rowspan="1">0.005</td><td char="." align="char" colspan="1" rowspan="1">1.030 (1.009&#8211;1.051)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">BMI</td><td char="." align="char" colspan="1" rowspan="1">0.093</td><td char="." align="char" colspan="1" rowspan="1">0.040</td><td char="." align="char" colspan="1" rowspan="1">0.020</td><td char="." align="char" colspan="1" rowspan="1">0.911 (0.843&#8211;0.985)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Hypertension</td><td char="." align="char" colspan="1" rowspan="1">0.036</td><td char="." align="char" colspan="1" rowspan="1">0.015</td><td char="." align="char" colspan="1" rowspan="1">0.012</td><td char="." align="char" colspan="1" rowspan="1">1.037 (1.008&#8211;1.067)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AF</td><td char="." align="char" colspan="1" rowspan="1">0.059</td><td char="." align="char" colspan="1" rowspan="1">0.036</td><td char="." align="char" colspan="1" rowspan="1">0.096</td><td char="." align="char" colspan="1" rowspan="1">1.061 (0.990&#8211;1.137)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">NT-proBNP</td><td char="." align="char" colspan="1" rowspan="1">0.000</td><td char="." align="char" colspan="1" rowspan="1">0.000</td><td char="." align="char" colspan="1" rowspan="1">0.015</td><td char="." align="char" colspan="1" rowspan="1">1.000 (1.000&#8722;1.001)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Serum creatinine</td><td char="." align="char" colspan="1" rowspan="1">0.020</td><td char="." align="char" colspan="1" rowspan="1">0.006</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td char="." align="char" colspan="1" rowspan="1">1.020 (1.007&#8211;1.032)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Cathepsin B</td><td char="." align="char" colspan="1" rowspan="1">1.264</td><td char="." align="char" colspan="1" rowspan="1">0.467</td><td char="." align="char" colspan="1" rowspan="1">0.007</td><td char="." align="char" colspan="1" rowspan="1">3.541 (1.419&#8211;8.838)</td></tr><tr><td align="left" colspan="1" rowspan="1">Multivariate</td><td align="left" colspan="1" rowspan="1">Age</td><td char="." align="char" colspan="1" rowspan="1">0.010</td><td char="." align="char" colspan="1" rowspan="1">0.027</td><td char="." align="char" colspan="1" rowspan="1">0.700</td><td char="." align="char" colspan="1" rowspan="1">0.990 (0.940&#8211;1.043)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">BMI</td><td char="." align="char" colspan="1" rowspan="1">0.052</td><td char="." align="char" colspan="1" rowspan="1">0.108</td><td char="." align="char" colspan="1" rowspan="1">0.632</td><td char="." align="char" colspan="1" rowspan="1">1.053 (0.852&#8211;1.303)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Hypertension</td><td char="." align="char" colspan="1" rowspan="1">0.024</td><td char="." align="char" colspan="1" rowspan="1">0.033</td><td char="." align="char" colspan="1" rowspan="1">0.472</td><td char="." align="char" colspan="1" rowspan="1">1.024 (0.960&#8211;1.092)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">NT-proBNP</td><td char="." align="char" colspan="1" rowspan="1">0.001</td><td char="." align="char" colspan="1" rowspan="1">0.000</td><td char="." align="char" colspan="1" rowspan="1">0.099</td><td char="." align="char" colspan="1" rowspan="1">1.001 (1.000&#8722;1.002)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Serum creatinine</td><td char="." align="char" colspan="1" rowspan="1">0.007</td><td char="." align="char" colspan="1" rowspan="1">0.011</td><td char="." align="char" colspan="1" rowspan="1">0.531</td><td char="." align="char" colspan="1" rowspan="1">0.993 (0.971&#8211;1.015)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Cathepsin B</td><td char="." align="char" colspan="1" rowspan="1">1.582</td><td char="." align="char" colspan="1" rowspan="1">0.657</td><td char="." align="char" colspan="1" rowspan="1">0.016</td><td char="." align="char" colspan="1" rowspan="1">4.863 (1.341&#8211;17.632)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SE</italic> standard error, <italic toggle="yes">OR</italic> odds ratio, <italic toggle="yes">95% CI</italic> confidence interval, <italic toggle="yes">BMI</italic> Body Mass Index, <italic toggle="yes">AF</italic> atrial fibrillation.</p></table-wrap-foot></table-wrap>
</p><p id="Par48">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>ROC curve analysis of cathepsin B protein levels in human PBLs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1339" position="float" orientation="portrait" xlink:href="41598_2025_17641_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec7"><title>Correlation analysis between the cathepsin B protein levels in PBLs and clinical indicators</title><p id="Par49">Spearman correlation analysis was conducted to evaluate the relationship between cathepsin B protein levels in PBLs and various clinical indicators. As illustrated in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>, cathepsin B protein levels were significantly associated with several echocardiographic parameters, including LAD (<italic toggle="yes">r</italic>&#8201;=&#8201;0.392, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), LVDD (<italic toggle="yes">r</italic>&#8201;=&#8201;0.320, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002), IVST (<italic toggle="yes">r</italic>&#8201;=&#8201;0.250, <italic toggle="yes">p</italic>&#8201;=&#8201;0.018), LVPWT (<italic toggle="yes">r</italic>&#8201;=&#8201;0.258, <italic toggle="yes">p</italic>&#8201;=&#8201;0.014), left ventricular mass index (LVMI) (<italic toggle="yes">r</italic>&#8201;=&#8201;0.384, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and LVEF (<italic toggle="yes">r</italic> = &#8722;0.442, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Additionally, cathepsin B protein levels were positively correlated with NT-proBNP (<italic toggle="yes">r</italic>&#8201;=&#8201;0.403, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002) and serum creatinine (<italic toggle="yes">r</italic>&#8201;=&#8201;0.241, <italic toggle="yes">p</italic>&#8201;=&#8201;0.024). In summary, cathepsin B protein levels in PBLs showed strong correlations with both cardiac and renal function indicators.</p><p id="Par50">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Spearman correlation analysis between the cathepsin B protein levels in PBLs and clinical indicators. The protein levels of cathepsin B in PBLs was measured by western blotting analysis. The shaded area represent 95% confidence bands. Annotation: CTSB, cathepsin B; LAD, left atrial diameter; LVDD, left ventricular end-diastolic dimension; IVST, interventricular septal thickness; LVPWT, left ventricular posterior wall thickness; LVMI, left ventricular mass index; LVEF, left ventricular ejection fraction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1406" position="float" orientation="portrait" xlink:href="41598_2025_17641_Fig4_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec8"><title>Discussion</title><p id="Par51">This study demonstrates that cathepsin B expression in PBLs positively correlates with its expression in the myocardial tissue and is up-regulated in patients with left ventricular hypertrophy (LVH), particularly in those with eccentric hypertrophy. Cathepsin B in PBLs may serve as a potential biomarker for diagnosing maladaptive cardiac hypertrophy.</p><p id="Par52">Pathological cardiac hypertrophy can contribute to heart failure, and both conditions are ultimately life-threatening. The compensatory stage of cardiac hypertrophy is typically characterized by LVH and ventricular wall thickening, whereas the decompensated stage involves ventricular dilation and impaired cardiac function<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. The transition from adaptive to maladaptive remodeling is accompanied by various changes in cardiomyocytes, including apoptosis, electrophysiological alterations, metabolic shifts, maladaptive gene expression, excessive autophagy, and fibrosis<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. Therefore, identifying clinically relevant mediators of maladaptive remodeling is essential for improving outcomes in patients with pathological hypertrophy and heart failure.</p><p id="Par53">Cathepsin B, a lysosomal cysteine protease, plays a vital role in numerous physiological processes beyond its proteolytic function in lysosomes, such as extracellular matrix degradation, innate immunity, and programmed cell death<sup><xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref></sup>. An increasing number of studies have highlighted the involvement of cathepsin B in cardiovascular pathologies, including hypertension, myocardial infarction, cardiomyopathies, and heart failure<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Upregulation of myocardial cathepsin B has been observed in both murine models of myocardial hypertrophy and in patients with dilated cardiomyopathy<sup><xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. However, it remains unknown whether cathepsin B is expressed in PBLs, and if so, whether it could serve as a peripheral biomarker for pathological cardiac hypertrophy. This study aimed to address these questions.</p><p id="Par54">Immunofluorescence staining confirmed the presence of cathepsin B in human PBLs. Western blotting was performed to detect the cathepsin B protein levels in myocardial tissues and PBLs. Interestingly, the results indicated that cathepsin B in myocardial tissues may be predominantly in double-chain form, whereas in PBLs, the protein might mainly be in mature single-chain form. The reason for this difference in expression might be related to different functional requirements of myocardial tissue and PBLs, as well as tissue-specific expression. Myocardial tissue has an active metabolism, continuous demand for protein turnover, and is rich in lysosomes. The low pH environment and cathepsin D in lysosomes can cleave single-chain cathepsin B into more active double-chain form<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. However, the lysosomal system in lymphocytes may not be as developed as that in myocardial cells, resulting in insufficient cleavage of single-chain cathepsin B. Additionally, lymphocytes may regulate the activation state of cathepsin B to avoid excessive inflammatory responses<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. We further found that its expression in PBLs was positively correlated with its expression in myocardial tissue, suggesting that cathepsin B levels in PBLs may reflect the expression levels in myocardium.</p><p id="Par55">Furthermore, we assessed the association between cathepsin B expression in PBLs and cardiac structure and function. The results showed significantly elevated cathepsin B levels in PBLs of patients with LVH, particularly in those with eccentric hypertrophy, an established manifestations of decompensated cardiac hypertrophy. These results suggested that cathepsin B expression in PBLs is associated with maladaptive hypertrophy. Increasing evidence suggests that cardiomyocyte death plays a role in the transition from compensatory to decompensated remodeling. This includes forms of cell death such as apoptosis, necrosis, autophagy, and pyroptosis<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Cathepsin B has been implicated in multiple forms of programmed cell death, including apoptosis, pyroptosis, ferroptosis, necroptosis, and autophagic cell death<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. We therefore hypothesized that cathepsin B may contribute to the development of decompensated hypertrophy by promoting cardiomyocyte death. Future research is warranted to investigate this hypothesis.</p><p id="Par56">Binary logistic regression and ROC curve analyses indicated that the protein level of cathepsin B in PBLs has diagnostic value for LVH. Our data indicated that a history of hypertension was not an independent risk factor for LVH, potentially due to adherence to anti-hypertensive therapy mitigating its effects on cardiac hypertrophy. Furthermore, multinomial logistic regression analysis identified cathepsin B protein levels as an independent factor influencing the progression of left ventricular geometry, further validating the role of cathepsin B in the pathogenesis of pathological cardiac hypertrophy.</p><p id="Par57">Additionally, we analyzed the correlation between cathepsin B protein levels in PBLs and other clinical indicators. Significant positive correlations were observed with cardiac structure and function parameters such as left atrial diameter (LAD), left ventricular end-diastolic dimension (LVDD), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular mass index (LVMI), and NT-proBNP. A significant negative correlation was observed with left ventricular ejection fraction (LVEF). Collectively, these findings suggest that cathepsin B in PBLs has potential as both a peripheral biomarker for diagnosing maladaptive myocardial hypertrophy and an indicator of cardiac function.</p><p id="Par58">Moreover, cathepsin B protein levels in PBLs positively correlated with serum creatinine levels. Previous studies have shown that cathepsin B is involved in renal remodeling in patients with diabetes or chronic kidney disease<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>, and serum cathepsin B levels have been associated with age-related decline in renal function in the general population<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. In our study, patients with overt renal insufficiency were excluded; therefore, elevated cathepsin B in PBLs may reflect subclinical renal dysfunction.</p><p id="Par59">This study has several limitations. The patient samples were obtained from a single center, which may introduce selection bias. Due to the difficulty in obtaining ventricular tissue, only the left atrial appendage samples were collected, potentially introducing additional bias. Moreover, while we observed a correlation between cathepsin B levels in PBLs and pathological cardiac hypertrophy, causality has yet to be established and warrants further investigation.</p><p id="Par60">In conclusion, to our knowledge, this study is the first to demonstrate that cathepsin B in PBLs may serve as a non-invasive biomarker for diagnosing maladaptive cardiac hypertrophy, offering valuable insights into disease progression and potential therapeutic monitoring. Further multi-center studies and mechanistic investigations are needed to validate and expand upon these findings.</p></sec><sec id="Sec9"><title>Methods</title><sec id="Sec10"><title>Subjects and samples</title><p id="Par61">A total of 225 hospitalized patients (68.5&#8201;&#177;&#8201;0.86 years, 63% male) were enrolled, with a mean Body Mass Index (BMI) of 24.89&#8201;&#177;&#8201;0.25&#160;kg/m&#178;. Among them, there were 30 patients who underwent heart valve surgery, their left atrial appendage tissue and preoperative venous blood were obtained. The remaining 195 patients were from the department of cardiology, their peripheral venous blood was collected. Inclusion criteria: the patients with hypertension, ischemic cardiomyopathy, or valvular heart disease, who were hospitalized in the Department of Cardiology and Cardiac Surgery of Shandong Provincial Hospital, and aged&#8201;&#8805;&#8201;18 years and signed informed consent. Exclusion criteria: the patients combined with acute heart failure, viral myocarditis, autoimmune diseases, malignant tumors, acute and chronic infections, severe liver and kidney insufficiency.</p><p id="Par62">The study was discussed and approved by the Ethics Committee of Shandong Provincial Hospital. We confirm that all methods were performed in accordance with the relevant guidelines and regulations.</p></sec><sec id="Sec11"><title>Echocardiography</title><p id="Par63">All the enrolled patients underwent color Doppler echocardiography in the cardiac ultrasound laboratory of our hospital, and the indicators of measurement were as follows: aod aortic dimension (AOD), right atrial diameter (RAD), right ventricular dimension (RVD), left atrial diameter (LAD), left ventricular end-diastolic dimension (LVDD), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular ejection fraction (LVEF).</p><p id="Par64">The body surface area (BSA), left ventricular mass (LVM), left ventricular mass index (LVMI) and left ventricular relative wall thickness (LVRWT) were calculated separately according to the following equations<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>.</p><p id="Par65">
<inline-formula id="IEq5"><alternatives><tex-math id="d33e1512">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$BSA\,=\,0.0061 \times H\left( {cm} \right)\,+\,0.0128 \times W\left( {kg} \right) - 0.1529$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq5.gif"/></alternatives></inline-formula></p><p id="Par66">(<italic toggle="yes">H</italic> is the height of the patient, and <italic toggle="yes">W</italic> is the weight of the patient.)</p><p id="Par67"><inline-formula id="IEq6"><alternatives><tex-math id="d33e1526">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$LVM = 0.8 \times 1.04 \times [(LVEDD{+}IVST{+}LVPWT)^{3} - LVEDD^{3} ]{+}0.6$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq6.gif"/></alternatives></inline-formula>
</p><p id="Par68">
<inline-formula id="IEq7"><alternatives><tex-math id="d33e1534">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$LVMI\,=\,LVM/BSA$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq7.gif"/></alternatives></inline-formula></p><p id="Par69">
<inline-formula id="IEq8"><alternatives><tex-math id="d33e1541">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$LVRWT=(2 \times LVPWT)/LVEDD$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq8.gif"/></alternatives></inline-formula></p><p id="Par70">LVH was defined as LVMI greater than 115&#160;g/m<sup>2</sup> in men or 95&#160;g/m<sup>2</sup> in women.</p></sec><sec id="Sec12"><title>Grouping</title><p id="Par71">The enrolled patients were divided into the LVH and non-LVH groups based on LVMI. According to LVMI and LVRWT (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>), the patients were classified into four groups: the normal geometry (NG), centripetal remodeling (CR), centripetal hypertrophy (CH), and eccentric hypertrophy (EH)<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>.</p><p id="Par72">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>The diagnostic criteria of LV geometrical configuration.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Geometry</th><th align="left" colspan="1" rowspan="1">LVMI (g/m<sup>2</sup>)</th><th align="left" colspan="1" rowspan="1">LVRWT</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">NG</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;115 (men), &lt;&#8201;95 (women)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.43</td></tr><tr><td align="left" colspan="1" rowspan="1">CR</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;115 (men), &lt;&#8201;95 (women)</td><td char="." align="char" colspan="1" rowspan="1">&#8805;&#8201;0.43</td></tr><tr><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;115 (men), &#8805;&#8201;95 (women)</td><td char="." align="char" colspan="1" rowspan="1">&#8805;&#8201;0.43</td></tr><tr><td align="left" colspan="1" rowspan="1">EH</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;115 (men), &#8805;&#8201;95 (women)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.43</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LVMI</italic> left ventricular mass index, <italic toggle="yes">LVRWT</italic> left ventricular relative wall thickness, <italic toggle="yes">NG</italic> normal geometry, <italic toggle="yes">CR</italic> centripetal remodeling, <italic toggle="yes">CH</italic> centripetal hypertrophy, <italic toggle="yes">EH</italic> eccentric hypertrophy.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Extraction of human peripheral blood lymphocytes</title><p id="Par73">5&#160;ml venous blood was collected from the enrolled patient and placed in the EDTA anticoagulant tube for the extraction of peripheral blood lymphocytes. The whole blood was diluted with 5&#160;ml PBS buffer, and 5&#160;ml of the Human Lymphocyte Separation Medium (Cat. No. P8900, Solarbio) was added to the centrifuge tube, then the diluted whole blood was slowly and gently transferred and flattened above the liquid level of the separation solution, centrifuged at 1000&#215;g for 30&#160;min at room temperature (RT). After centrifugation, there is a distinct stratification: the top layer is the diluted plasma, the middle layer is the separation medium, the white film layer between the plasma and the separation medium is the lymphocytes layer, and the bottom layer is the red blood cells and granulocytes. The white film layer was carefully aspirated into a centrifuge tube containing 10&#160;ml PBS buffer and then centrifuged at 250&#215;g for 10&#160;min at RT. Subsequently, the cell precipitate was washed again. The lymphocytes were retained for subsequent operations.</p></sec><sec id="Sec14"><title>Immunofluorescence staining</title><p id="Par74">Collected peripheral blood lymphocytes were fixed with 4% paraformaldehyde for 15&#160;min and subsequently washed three times with PBS. Cells were resuspended with PBS buffer, and 50ul of the cell suspension was dropped onto poly-L-lysine coated slide (Cat. No. YA0170, Solarbio) and dried naturally at RT. Then, they were permeated with 0.4% Triton X-100 (Cat. No. P0096, Beyotime) for 30&#160;min and blocked in 2% BSA (Cat. No. ST2249, Beyotime) for 1&#160;h at RT. Cell samples was incubated overnight with anti-cathepsin B (1:300) (Cat. No. 12216-1-AP, Proteintch) at 4&#8451;. The no-primary control group was incubated overnight by 2% BSA at 4&#8451;. After washed with PBS for three times, the cells were incubated with CoraLite594-conjugated secondary antibodies for 1&#160;h at RT. The cell nuclei were stained with DAPI for 10&#160;min at RT. Images were acquired using a positive fluorescence microscope (OLYMPUS BX63).</p></sec><sec id="Sec15"><title>Quantitative polymerase chain reaction (qPCR)</title><p id="Par75">Total RNA from PBLs were isolated using RNA isolater Total RNA (Cat. No. R711-01, Vazyme Biotech Co., Ltd.). The cDNA was prepared using the HiScript III RT SuperMix for qPCR (+&#8201;gDNA wiper) (Cat. No. R323-01, Vazyme Biotech Co., Ltd.). The primer sequences used for qPCR are listed in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>. The PCR was carried out with cDNA using SYBR Green Premix Pro Taq HS qPCR Kit (Cat. No. AG11718, Accurate Biotechnology, Co., Ltd). The amplification procedure was 30&#160;s at 95&#8451;, then followed by 40 cycles of 10&#160;s at 95&#8451; and 30&#160;s at 60&#8451;. Thermal cycling and fluorescence detection were performed by QuantStudioTM 12&#160;K Flex. The level of cathepsin B was normalized to GAPDH. The relative mRNA expression of cathepsin B were calculated using the 2&#8722;&#8710;&#8710;Ct method.</p><p id="Par76">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>The primer sequences used for qPCR.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Gene</th><th align="left" colspan="1" rowspan="1">Sequence</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Cathepsin B-human</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">5&#8217;-TTCTTGCGACTCTTGGGACTTC&#8722;3&#8217;</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">5&#8217;-TGACGAGGATGACAGGGAACTA&#8722;3&#8217;</td></tr><tr><td align="left" colspan="1" rowspan="1">GAPDH-human</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">F</td><td align="left" colspan="1" rowspan="1">5&#8217;-CTGCACCACCAACTGCTTAG&#8722;3&#8217;</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">5&#8217;-AGGTCCACCACTGACACGTT&#8722;3&#8217;</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec16"><title>Western blotting analysis</title><p id="Par77">The human PBLs and myocardial tissue were homogenized in RIPA lysis buffer (Cat. No. P0013B, Beyotime) and phenylmethane sulfonyl fluoride (Cat. No. ST506, Beyotime). Then, the cell lysate was centrifuged at 12,000&#215;g for 15&#160;min at 4&#8451;and the supernatant was retained. The protein concentration was quantified by BCA Protein Assay Kit (Cat. No. P0012, Beyotime). Protein samples were separated by 10% SDS-PAGE gel (Cat. No. PG112, Epizyme), and then transferred to PVDF membranes (Cat. No. IPVH00010, Millipore). The PVDF membranes were blocked by 5% skim milk for 1&#160;h at RT and subsequently incubated with specific primary antibodies for 10&#8211;15&#160;h at 4&#8451;. The primary antibodies were used as follows: anti-cathepsin B (1:2500) (Cat. No. 12216-1-AP, Proteintch) and anti-Alpha Tubulin (1:5000) (Cat. No. 11224-1-AP, Proteintch). After that, the membranes were washed with Tris-buffered saline containing 1% Tween-20 (TBST) for three times, and then incubated with secondary antibody (1:10000) (Cat. No. PR30011, Proteintch) for 1&#160;h at RT. Subsequently, the membranes were washed with TBST for three times. Western blotting results were detected with chemiluminescent analyzer (ProteinSimple, USA) and immunoblot intensities were analyzed with ImageJ v1.8.0.112 software (National Institutes of Health). Cathepsin B protein levels were calculated by the ratio of the gray value of its protein band to the gray value of tubulin.</p></sec><sec id="Sec17"><title>Statistical analysis</title><p id="Par78">The IBM SPSS Statistics 25 was used for statistical analysis. Measurement data with normal distribution were represented as mean&#8201;&#177;&#8201;standard deviation (<inline-formula id="IEq9"><alternatives><tex-math id="d33e1704">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:\stackrel{-}{x}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_Article_IEq1.gif"/></alternatives></inline-formula> &#177;&#3923;), and the comparison among two groups was analyzed using the unpaired t test and four groups was using one-way ANOVA; The measurement data with non-normal distribution were expressed as median (interquartile range, IQR), and the comparison two groups was analyzed using the Mann-Whitney U test and four groups was using Kruskal-Wallis test. The count data were presented as numbers and percentages (%), and the comparison among groups was performed using the Chi-square (&#967;<sup>2</sup>) test. Binary logistic regression analysis was used to identify the influencing factors of LVH. The diagnostic efficacy of cathepsin B protein levels in PBLs for LVH was evaluated by the ROC curve analysis. Two-sided test, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec18" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17641_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CTSB</term><def><p id="Par9">Cathepsin B</p></def></def-item><def-item><term>PBLs</term><def><p id="Par10">Human peripheral blood lymphocytes</p></def></def-item><def-item><term>LVH</term><def><p id="Par11">Left ventricular hypertrophy</p></def></def-item><def-item><term>LVMI</term><def><p id="Par12">Left ventricular mass index</p></def></def-item><def-item><term>BMI</term><def><p id="Par13">Body Mass Index</p></def></def-item><def-item><term>AOD</term><def><p id="Par14">Aod aortic dimension</p></def></def-item><def-item><term>RAD</term><def><p id="Par15">Right atrial diameter</p></def></def-item><def-item><term>RVD</term><def><p id="Par16">Right ventricular dimension</p></def></def-item><def-item><term>LAD</term><def><p id="Par17">Left atrial diameter</p></def></def-item><def-item><term>LVDD</term><def><p id="Par18">Left ventricular end-diastolic dimension</p></def></def-item><def-item><term>IVST</term><def><p id="Par19">Interventricular septal thickness</p></def></def-item><def-item><term>LVPWT</term><def><p id="Par20">Left ventricular posterior wall thickness</p></def></def-item><def-item><term>LVEF</term><def><p id="Par21">Left ventricular ejection fraction</p></def></def-item><def-item><term>BSA</term><def><p id="Par22">Body surface area</p></def></def-item><def-item><term>LVM</term><def><p id="Par23">Left ventricular mass</p></def></def-item><def-item><term>LVMI</term><def><p id="Par24">Left ventricular mass index</p></def></def-item><def-item><term>LVRWT</term><def><p id="Par25">Left ventricular relative wall thickness</p></def></def-item><def-item><term>IQR</term><def><p id="Par26">Interquartile range</p></def></def-item><def-item><term>QPCR</term><def><p id="Par27">Quantitative real-time polymerase chain reaction</p></def></def-item><def-item><term>RT</term><def><p id="Par28">Room temperature</p></def></def-item><def-item><term>TBST</term><def><p id="Par29">Tris-buffered saline containing 1% Tween-20</p></def></def-item><def-item><term>ROC</term><def><p id="Par30">The receiver operating characteristic</p></def></def-item><def-item><term>CAD</term><def><p id="Par31">Coronary atherosclerotic heart disease</p></def></def-item><def-item><term>AF</term><def><p id="Par32">Atrial fibrillation</p></def></def-item><def-item><term>NG</term><def><p id="Par33">Normal conformation</p></def></def-item><def-item><term>CR</term><def><p id="Par34">Centripetal remodelling</p></def></def-item><def-item><term>CH</term><def><p id="Par35">Centripetal hypertrophy</p></def></def-item><def-item><term>EH</term><def><p id="Par36">Eccentric hypertrophy</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank all patients who agreed to provide samples for this study. We are extremely grateful to the relative clinicians, nurses in Shandong Provincial Hospital Affiliated to Shandong First Medical University for their contributions during the sample collection process. We also would like to thank Editage (www.editage.cn) for English language editing.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>DF: Investigation, Data curation, Formal analysis, Validation, Visualization, and Writing-original draft; DF, CL, WG, SZ, YW, and GZ: Sample selection; DF, YS, YD and JW: Conceptualization, Methodology, Project administration, and Writing-review and editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Key Research and Development Program of China [grant number 2020YFC2008900].</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par79">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par80">This study was approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University. Written informed consent was also obtained from the patient for the acquisition of blood and left atrial appendage specimens.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>J</given-names></name><etal/></person-group><article-title>HECT (Homologous to the E6-AP carboxyl Terminus)-Type ubiquitin E3 ligase ITCH attenuates cardiac hypertrophy by suppressing the Wnt/&#946;-Catenin signaling pathway</article-title><source>Hypertension</source><year>2020</year><volume>76</volume><issue>6</issue><fpage>1868</fpage><lpage>1878</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15487</pub-id><pub-id pub-id-type="pmid">33131309</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Goto, J. et al. HECT (Homologous to the E6-AP carboxyl Terminus)-Type ubiquitin E3 ligase ITCH attenuates cardiac hypertrophy by suppressing the Wnt/&#946;-Catenin signaling pathway. <italic toggle="yes">Hypertension</italic><bold>76</bold> (6), 1868&#8211;1878 (2020).<pub-id pub-id-type="pmid">33131309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.120.15487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#272;or&#273;evi&#263;</surname><given-names>DB</given-names></name><name name-style="western"><surname>Kora&#269;evi&#263;</surname><given-names>GP</given-names></name><name name-style="western"><surname>&#272;or&#273;evi&#263;</surname><given-names>AD</given-names></name><name name-style="western"><surname>Lovi&#263;</surname><given-names>DB</given-names></name></person-group><article-title>Hypertension and left ventricular hypertrophy</article-title><source>J. Hypertens.</source><year>2024</year><volume>42</volume><issue>9</issue><fpage>1505</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000003774</pub-id><pub-id pub-id-type="pmid">38747417</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">&#272;or&#273;evi&#263;, D. B., Kora&#269;evi&#263;, G. P., &#272;or&#273;evi&#263;, A. D. &amp; Lovi&#263;, D. B. Hypertension and left ventricular hypertrophy. <italic toggle="yes">J. Hypertens.</italic><bold>42</bold> (9), 1505&#8211;1515 (2024).<pub-id pub-id-type="pmid">38747417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HJH.0000000000003774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiattarella</surname><given-names>GG</given-names></name><name name-style="western"><surname>Hill</surname><given-names>JA</given-names></name></person-group><article-title>Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload</article-title><source>Circulation</source><year>2015</year><volume>131</volume><issue>16</issue><fpage>1435</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.013894</pub-id><pub-id pub-id-type="pmid">25901069</pub-id><pub-id pub-id-type="pmcid">PMC4408778</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Schiattarella, G. G. &amp; Hill, J. A. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. <italic toggle="yes">Circulation</italic><bold>131</bold> (16), 1435&#8211;1447 (2015).<pub-id pub-id-type="pmid">25901069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.115.013894</pub-id><pub-id pub-id-type="pmcid">PMC4408778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Heart failure</article-title><source>JACC Heart Fail.</source><year>2013</year><volume>1</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2012.10.002</pub-id><pub-id pub-id-type="pmid">24621794</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Braunwald, E. Heart failure. <italic toggle="yes">JACC Heart Fail.</italic><bold>1</bold> (1), 1&#8211;20 (2013).<pub-id pub-id-type="pmid">24621794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jchf.2012.10.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cluntun</surname><given-names>AA</given-names></name><etal/></person-group><article-title>The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure</article-title><source>Cell Metabol.</source><year>2021</year><volume>33</volume><issue>3</issue><fpage>629</fpage><lpage>648e10</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.12.003</pub-id><pub-id pub-id-type="pmcid">PMC7933116</pub-id><pub-id pub-id-type="pmid">33333007</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Cluntun, A. A. et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. <italic toggle="yes">Cell Metabol.</italic><bold>33</bold> (3), 629&#8211;648e10 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2020.12.003</pub-id><pub-id pub-id-type="pmcid">PMC7933116</pub-id><pub-id pub-id-type="pmid">33333007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oldfield</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Duhamel</surname><given-names>TA</given-names></name><name name-style="western"><surname>Dhalla</surname><given-names>NS</given-names></name></person-group><article-title>Mechanisms for the transition from physiological to pathological cardiac hypertrophy</article-title><source>Can. J. Physiol. Pharmacol.</source><year>2020</year><volume>98</volume><issue>2</issue><fpage>74</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1139/cjpp-2019-0566</pub-id><pub-id pub-id-type="pmid">31815523</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Oldfield, C. J., Duhamel, T. A. &amp; Dhalla, N. S. Mechanisms for the transition from physiological to pathological cardiac hypertrophy. <italic toggle="yes">Can. J. Physiol. Pharmacol.</italic><bold>98</bold> (2), 74&#8211;84 (2020).<pub-id pub-id-type="pmid">31815523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1139/cjpp-2019-0566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turk</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cysteine cathepsins: from structure, function and regulation to new frontiers</article-title><source>Biochim. Biophys. Acta</source><year>2012</year><volume>1824</volume><issue>1</issue><fpage>68</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2011.10.002</pub-id><pub-id pub-id-type="pmid">22024571</pub-id><pub-id pub-id-type="pmcid">PMC7105208</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Turk, V. et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. <italic toggle="yes">Biochim. Biophys. Acta</italic>. <bold>1824</bold> (1), 68&#8211;88 (2012).<pub-id pub-id-type="pmid">22024571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbapap.2011.10.002</pub-id><pub-id pub-id-type="pmcid">PMC7105208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musil</surname><given-names>D</given-names></name><etal/></person-group><article-title>The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity</article-title><source>EMBO J.</source><year>1991</year><volume>10</volume><issue>9</issue><fpage>2321</fpage><lpage>2330</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1991.tb07771.x</pub-id><pub-id pub-id-type="pmid">1868826</pub-id><pub-id pub-id-type="pmcid">PMC452927</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Musil, D. et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. <italic toggle="yes">EMBO J.</italic><bold>10</bold> (9), 2321&#8211;2330 (1991).<pub-id pub-id-type="pmid">1868826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1460-2075.1991.tb07771.x</pub-id><pub-id pub-id-type="pmcid">PMC452927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Piezo1-Mediated mechanotransduction promotes cardiac hypertrophy by impairing calcium homeostasis to activate calpain/calcineurin signaling</article-title><source>Hypertens. (Dallas Tex. : 1979)</source><year>2021</year><volume>78</volume><issue>3</issue><fpage>647</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.121.17177</pub-id><pub-id pub-id-type="pmid">34333987</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zhang, Y. et al. Piezo1-Mediated mechanotransduction promotes cardiac hypertrophy by impairing calcium homeostasis to activate calpain/calcineurin signaling. <italic toggle="yes">Hypertens. (Dallas Tex. : 1979)</italic>. <bold>78</bold> (3), 647&#8211;660 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.121.17177</pub-id><pub-id pub-id-type="pmid">34333987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hook</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cathepsin B in neurodegeneration of alzheimer&#8217;s disease, traumatic brain injury, and related brain disorders. Biochimica et biophysica acta</article-title><source>Proteins Proteom.</source><year>2020</year><volume>1868</volume><issue>8</issue><fpage>140428</fpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2020.140428</pub-id><pub-id pub-id-type="pmcid">PMC7261628</pub-id><pub-id pub-id-type="pmid">32305689</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hook, V. et al. Cathepsin B in neurodegeneration of alzheimer&#8217;s disease, traumatic brain injury, and related brain disorders. Biochimica et biophysica acta. <italic toggle="yes">Proteins Proteom.</italic><bold>1868</bold> (8), 140428 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbapap.2020.140428</pub-id><pub-id pub-id-type="pmcid">PMC7261628</pub-id><pub-id pub-id-type="pmid">32305689</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sevenich</surname><given-names>L</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>JA</given-names></name></person-group><article-title>Pericellular proteolysis in cancer</article-title><source>Genes Dev.</source><year>2014</year><volume>28</volume><issue>21</issue><fpage>2331</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1101/gad.250647.114</pub-id><pub-id pub-id-type="pmid">25367033</pub-id><pub-id pub-id-type="pmcid">PMC4215179</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Sevenich, L. &amp; Joyce, J. A. Pericellular proteolysis in cancer. <italic toggle="yes">Genes Dev.</italic><bold>28</bold> (21), 2331&#8211;2347 (2014).<pub-id pub-id-type="pmid">25367033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.250647.114</pub-id><pub-id pub-id-type="pmcid">PMC4215179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Targeting Calpain for heart failure therapy: implications from multiple murine models</article-title><source>JACC Basic. Translational Sci.</source><year>2018</year><volume>3</volume><issue>4</issue><fpage>503</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2018.05.004</pub-id><pub-id pub-id-type="pmcid">PMC6115647</pub-id><pub-id pub-id-type="pmid">30175274</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Wang, Y. et al. Targeting Calpain for heart failure therapy: implications from multiple murine models. <italic toggle="yes">JACC Basic. Translational Sci.</italic><bold>3</bold> (4), 503&#8211;517 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacbts.2018.05.004</pub-id><pub-id pub-id-type="pmcid">PMC6115647</pub-id><pub-id pub-id-type="pmid">30175274</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Letavernier</surname><given-names>E</given-names></name><etal/></person-group><article-title>Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension</article-title><source>Circul. Res.</source><year>2008</year><volume>102</volume><issue>6</issue><fpage>720</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.160077</pub-id><pub-id pub-id-type="pmid">18258859</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Letavernier, E. et al. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. <italic toggle="yes">Circul. Res.</italic><bold>102</bold> (6), 720&#8211;728 (2008).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.107.160077</pub-id><pub-id pub-id-type="pmid">18258859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Silica nanoparticles induce pyroptosis and cardiac hypertrophy via ROS/NLRP3/Caspase-1 pathway</article-title><source>Free Radic. Biol. Med.</source><year>2022</year><volume>182</volume><fpage>171</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2022.02.027</pub-id><pub-id pub-id-type="pmid">35219847</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Wang, F. et al. Silica nanoparticles induce pyroptosis and cardiac hypertrophy via ROS/NLRP3/Caspase-1 pathway. <italic toggle="yes">Free Radic. Biol. Med.</italic><bold>182</bold>, 171&#8211;181 (2022).<pub-id pub-id-type="pmid">35219847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2022.02.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutgens</surname><given-names>SP</given-names></name><name name-style="western"><surname>Cleutjens</surname><given-names>KB</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Heeneman</surname><given-names>S</given-names></name></person-group><article-title>Cathepsin cysteine proteases in cardiovascular disease</article-title><source>FASEB Journal: Official Publication Federation Am. Soc. Experimental Biology</source><year>2007</year><volume>21</volume><issue>12</issue><fpage>3029</fpage><lpage>3041</lpage><pub-id pub-id-type="doi">10.1096/fj.06-7924com</pub-id><pub-id pub-id-type="pmid">17522380</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Lutgens, S. P., Cleutjens, K. B., Daemen, M. J. &amp; Heeneman, S. Cathepsin cysteine proteases in cardiovascular disease. <italic toggle="yes">FASEB Journal: Official Publication Federation Am. Soc. Experimental Biology</italic>. <bold>21</bold> (12), 3029&#8211;3041 (2007).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.06-7924com</pub-id><pub-id pub-id-type="pmid">17522380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Toole</surname><given-names>D</given-names></name><etal/></person-group><article-title>Signalling pathways linking cysteine cathepsins to adverse cardiac remodelling</article-title><source>Cell. Signal.</source><year>2020</year><volume>76</volume><fpage>109770</fpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109770</pub-id><pub-id pub-id-type="pmid">32891693</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">O&#8217;Toole, D. et al. Signalling pathways linking cysteine cathepsins to adverse cardiac remodelling. <italic toggle="yes">Cell. Signal.</italic><bold>76</bold>, 109770 (2020).<pub-id pub-id-type="pmid">32891693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellsig.2020.109770</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>QQ</given-names></name><etal/></person-group><article-title>Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-&#945;/ASK1/JNK pathway</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2015</year><volume>308</volume><issue>9</issue><fpage>H1143</fpage><lpage>H1154</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00601.2014</pub-id><pub-id pub-id-type="pmid">25713304</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wu, Q. Q. et al. Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-&#945;/ASK1/JNK pathway. <italic toggle="yes">Am. J. Physiol. Heart Circ. Physiol.</italic><bold>308</bold> (9), H1143&#8211;H1154 (2015).<pub-id pub-id-type="pmid">25713304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpheart.00601.2014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L</given-names></name></person-group><article-title>Cathepsin B Inhibition attenuates cardiac dysfunction and remodeling following myocardial infarction by inhibiting the NLRP3 pathway</article-title><source>Mol. Med. Rep.</source><year>2017</year><volume>16</volume><issue>5</issue><fpage>7873</fpage><pub-id pub-id-type="doi">10.3892/mmr.2017.7551</pub-id><pub-id pub-id-type="pmid">28944892</pub-id><pub-id pub-id-type="pmcid">PMC5865890</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liu, A., Gao, X., Zhang, Q. &amp; Cui, L. Cathepsin B Inhibition attenuates cardiac dysfunction and remodeling following myocardial infarction by inhibiting the NLRP3 pathway. <italic toggle="yes">Mol. Med. Rep.</italic><bold>16</bold> (5), 7873 (2017).<pub-id pub-id-type="pmid">28944892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2017.7551</pub-id><pub-id pub-id-type="pmcid">PMC5865890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>XW</given-names></name><etal/></person-group><article-title>Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication</article-title><source>Circulation</source><year>2012</year><volume>125</volume><issue>12</issue><fpage>1551</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.066712</pub-id><pub-id pub-id-type="pmid">22451605</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Cheng, X. W. et al. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. <italic toggle="yes">Circulation</italic><bold>125</bold> (12), 1551&#8211;1562 (2012).<pub-id pub-id-type="pmid">22451605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.111.066712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><etal/></person-group><article-title>Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy</article-title><source>Eur. J. Heart Fail.</source><year>2006</year><volume>8</volume><issue>3</issue><fpage>284</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.ejheart.2005.09.004</pub-id><pub-id pub-id-type="pmid">16480925</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ge, J. et al. Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy. <italic toggle="yes">Eur. J. Heart Fail.</italic><bold>8</bold> (3), 284&#8211;289 (2006).<pub-id pub-id-type="pmid">16480925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejheart.2005.09.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Li, C. et al. Relationship between calcineurin - nuclear factor of activated T cells pathway and atrial fibrillation in patients with valvular heart disease. <italic toggle="yes">J. Shandong Univ. (Med Edition)&#160;</italic>8, 47&#8211;51. (2014).</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>MM</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name></person-group><article-title>A preliminary report on the correlation between calcineurin Mrna levels in peripheral blood lymphocytes and myocardial tissue in patients with heart failure</article-title><source>Chin. J. Circulation</source><year>2008</year><volume>02</volume><fpage>113</fpage><lpage>116</lpage></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wang, M. M., Zhao, Y., Liu, W., Zhang, J. &amp; Wang, J. C. A preliminary report on the correlation between calcineurin Mrna levels in peripheral blood lymphocytes and myocardial tissue in patients with heart failure. <italic toggle="yes">Chin. J. Circulation</italic>. <bold>02</bold>, 113&#8211;116 (2008).</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tham</surname><given-names>YK</given-names></name><name name-style="western"><surname>Bernardo</surname><given-names>BC</given-names></name><name name-style="western"><surname>Ooi</surname><given-names>JY</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>KL</given-names></name><name name-style="western"><surname>McMullen</surname><given-names>JR</given-names></name></person-group><article-title>Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets</article-title><source>Arch. Toxicol.</source><year>2015</year><volume>89</volume><issue>9</issue><fpage>1401</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1007/s00204-015-1477-x</pub-id><pub-id pub-id-type="pmid">25708889</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Tham, Y. K., Bernardo, B. C., Ooi, J. Y., Weeks, K. L. &amp; McMullen, J. R. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. <italic toggle="yes">Arch. Toxicol.</italic><bold>89</bold> (9), 1401&#8211;1438 (2015).<pub-id pub-id-type="pmid">25708889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-015-1477-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sloane</surname><given-names>BF</given-names></name><etal/></person-group><article-title>Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment</article-title><source>Semin Cancer Biol.</source><year>2005</year><volume>15</volume><issue>2</issue><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2004.08.001</pub-id><pub-id pub-id-type="pmid">15652460</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Sloane, B. F. et al. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. <italic toggle="yes">Semin Cancer Biol.</italic><bold>15</bold> (2), 149&#8211;157 (2005).<pub-id pub-id-type="pmid">15652460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2004.08.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>MY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>An</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>JG</given-names></name></person-group><article-title>B cell peripheral tolerance is promoted by cathepsin B protease</article-title><source>Proc. Natl. Acad. Sci. U S A</source><year>2023</year><volume>120</volume><issue>16</issue><fpage>e2300099120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2300099120</pub-id><pub-id pub-id-type="pmid">37040412</pub-id><pub-id pub-id-type="pmcid">PMC10120085</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Chou, M. Y., Liu, D., An, J., Xu, Y. &amp; Cyster, J. G. B cell peripheral tolerance is promoted by cathepsin B protease. <italic toggle="yes">Proc. Natl. Acad. Sci. U S A</italic>. <bold>120</bold> (16), e2300099120 (2023).<pub-id pub-id-type="pmid">37040412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2300099120</pub-id><pub-id pub-id-type="pmcid">PMC10120085</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cathepsin B promotes sepsis-induced acute kidney injury through activating mitochondrial apoptosis pathway</article-title><source>Front. Immunol.</source><year>2023</year><volume>13</volume><fpage>1053754</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.1053754</pub-id><pub-id pub-id-type="pmid">36713420</pub-id><pub-id pub-id-type="pmcid">PMC9880165</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wang, Y. et al. Cathepsin B promotes sepsis-induced acute kidney injury through activating mitochondrial apoptosis pathway. <italic toggle="yes">Front. Immunol.</italic><bold>13</bold>, 1053754 (2023).<pub-id pub-id-type="pmid">36713420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1053754</pub-id><pub-id pub-id-type="pmcid">PMC9880165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Man</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><article-title>Regulation of lysosomal dynamics and autophagy by cathepsin b/cathepsin B</article-title><source>Autophagy</source><year>2016</year><volume>12</volume><issue>12</issue><fpage>2504</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1080/15548627.2016.1239679</pub-id><pub-id pub-id-type="pmid">27786577</pub-id><pub-id pub-id-type="pmcid">PMC5173259</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Man, S. M. &amp; Kanneganti, T. D. Regulation of lysosomal dynamics and autophagy by cathepsin b/cathepsin B. <italic toggle="yes">Autophagy</italic><bold>12</bold> (12), 2504&#8211;2505 (2016).<pub-id pub-id-type="pmid">27786577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2016.1239679</pub-id><pub-id pub-id-type="pmcid">PMC5173259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cathepsin B aggravates acute pancreatitis by activating the NLRP3 inflammasome and promoting the caspase-1-induced pyroptosis</article-title><source>Int. Immunopharmacol.</source><year>2021</year><volume>94</volume><fpage>107496</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2021.107496</pub-id><pub-id pub-id-type="pmid">33639565</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wang, J. et al. Cathepsin B aggravates acute pancreatitis by activating the NLRP3 inflammasome and promoting the caspase-1-induced pyroptosis. <italic toggle="yes">Int. Immunopharmacol.</italic><bold>94</bold>, 107496 (2021).<pub-id pub-id-type="pmid">33639565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2021.107496</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis</article-title><source>PLoS Pathog</source><year>2018</year><volume>14</volume><issue>1</issue><fpage>e1006872</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1006872</pub-id><pub-id pub-id-type="pmid">29360865</pub-id><pub-id pub-id-type="pmcid">PMC5809100</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Wang, Y. et al. Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis. <italic toggle="yes">PLoS Pathog</italic>. <bold>14</bold> (1), e1006872 (2018).<pub-id pub-id-type="pmid">29360865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1006872</pub-id><pub-id pub-id-type="pmcid">PMC5809100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>Cathepsin B in cardiovascular disease: underlying mechanisms and therapeutic strategies</article-title><source>J. Cell. Mol. Med.</source><year>2024</year><volume>28</volume><issue>17</issue><fpage>e70064</fpage><pub-id pub-id-type="doi">10.1111/jcmm.70064</pub-id><pub-id pub-id-type="pmid">39248527</pub-id><pub-id pub-id-type="pmcid">PMC11382359</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Cai, Z., Xu, S. &amp; Liu, C. Cathepsin B in cardiovascular disease: underlying mechanisms and therapeutic strategies. <italic toggle="yes">J. Cell. Mol. Med.</italic><bold>28</bold> (17), e70064 (2024).<pub-id pub-id-type="pmid">39248527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.70064</pub-id><pub-id pub-id-type="pmcid">PMC11382359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoka</surname><given-names>V</given-names></name><name name-style="western"><surname>Turk</surname><given-names>V</given-names></name><name name-style="western"><surname>Turk</surname><given-names>B</given-names></name></person-group><article-title>Lysosomal cathepsins and their regulation in aging and neurodegeneration</article-title><source>Ageing Res. Rev.</source><year>2016</year><volume>32</volume><fpage>22</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2016.04.010</pub-id><pub-id pub-id-type="pmid">27125852</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Stoka, V., Turk, V. &amp; Turk, B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. <italic toggle="yes">Ageing Res. Rev.</italic><bold>32</bold>, 22&#8211;37 (2016).<pub-id pub-id-type="pmid">27125852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2016.04.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turk</surname><given-names>V</given-names></name><name name-style="western"><surname>Turk</surname><given-names>B</given-names></name><name name-style="western"><surname>Turk</surname><given-names>D</given-names></name></person-group><article-title>Lysosomal cysteine proteases: facts and opportunities</article-title><source>EMBO J.</source><year>2001</year><volume>20</volume><issue>17</issue><fpage>4629</fpage><lpage>4633</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.17.4629</pub-id><pub-id pub-id-type="pmid">11532926</pub-id><pub-id pub-id-type="pmcid">PMC125585</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Turk, V., Turk, B. &amp; Turk, D. Lysosomal cysteine proteases: facts and opportunities. <italic toggle="yes">EMBO J.</italic><bold>20</bold> (17), 4629&#8211;4633 (2001).<pub-id pub-id-type="pmid">11532926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/emboj/20.17.4629</pub-id><pub-id pub-id-type="pmcid">PMC125585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Anti-hypertrophic effect of Na+/H&#8201;+&#8201;exchanger-1 Inhibition is mediated by reduced cathepsin B</article-title><source>Eur. J. Pharmacol.</source><year>2020</year><volume>888</volume><fpage>173420</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173420</pub-id><pub-id pub-id-type="pmid">32781168</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Riaz, S. et al. Anti-hypertrophic effect of Na+/H&#8201;+&#8201;exchanger-1 Inhibition is mediated by reduced cathepsin B. <italic toggle="yes">Eur. J. Pharmacol.</italic><bold>888</bold>, 173420 (2020).<pub-id pub-id-type="pmid">32781168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2020.173420</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diwan</surname><given-names>A</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>GW</given-names></name></person-group><article-title>Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets</article-title><source>Physiol. (Bethesda)</source><year>2007</year><volume>22</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physiol.00033.2006</pub-id><pub-id pub-id-type="pmid">17289931</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Diwan, A. &amp; Dorn, G. W. 2 Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. <italic toggle="yes">Physiol. (Bethesda)</italic>. <bold>22</bold>, 56&#8211;64 (2007).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physiol.00033.2006</pub-id><pub-id pub-id-type="pmid">17289931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>C</given-names></name><etal/></person-group><article-title>SerpinB1 targeting safeguards against pathological cardiac hypertrophy and remodelling by suppressing cardiomyocyte pyroptosis and inflammation initiation</article-title><source>Cardiovasc. Res.</source><year>2025</year><volume>121</volume><issue>1</issue><fpage>113</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvae241</pub-id><pub-id pub-id-type="pmid">39688818</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Lan, C. et al. SerpinB1 targeting safeguards against pathological cardiac hypertrophy and remodelling by suppressing cardiomyocyte pyroptosis and inflammation initiation. <italic toggle="yes">Cardiovasc. Res.</italic><bold>121</bold> (1), 113&#8211;127 (2025).<pub-id pub-id-type="pmid">39688818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvae241</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways</article-title><source>Cell. Death Dis.</source><year>2023</year><volume>14</volume><issue>4</issue><fpage>255</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-05786-0</pub-id><pub-id pub-id-type="pmid">37031185</pub-id><pub-id pub-id-type="pmcid">PMC10082344</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Xie, Z. et al. Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways. <italic toggle="yes">Cell. Death Dis.</italic><bold>14</bold> (4), 255 (2023).<pub-id pub-id-type="pmid">37031185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-05786-0</pub-id><pub-id pub-id-type="pmcid">PMC10082344</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musante</surname><given-names>L</given-names></name><etal/></person-group><article-title>Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy</article-title><source>J. Diabetes Res.</source><year>2015</year><volume>2015</volume><fpage>289734</fpage><pub-id pub-id-type="doi">10.1155/2015/289734</pub-id><pub-id pub-id-type="pmid">25874235</pub-id><pub-id pub-id-type="pmcid">PMC4383158</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Musante, L. et al. Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy. <italic toggle="yes">J. Diabetes Res.</italic><bold>2015</bold>, 289734 (2015).<pub-id pub-id-type="pmid">25874235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/289734</pub-id><pub-id pub-id-type="pmcid">PMC4383158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><etal/></person-group><article-title>The association of serum cathepsin B concentration with age-related cardiovascular-renal subclinical state in a healthy Chinese population</article-title><source>Arch. Gerontol. Geriatr.</source><year>2016</year><volume>65</volume><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.archger.2016.03.015</pub-id><pub-id pub-id-type="pmid">27032082</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wang, N. et al. The association of serum cathepsin B concentration with age-related cardiovascular-renal subclinical state in a healthy Chinese population. <italic toggle="yes">Arch. Gerontol. Geriatr.</italic><bold>65</bold>, 146&#8211;155 (2016).<pub-id pub-id-type="pmid">27032082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.archger.2016.03.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Body mass index, left ventricular mass index and cardiovascular events in chronic kidney disease</article-title><source>Am. J. Med. Sci.</source><year>2016</year><volume>351</volume><issue>1</issue><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.amjms.2015.10.004</pub-id><pub-id pub-id-type="pmid">26802763</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Chen, S. C. et al. Body mass index, left ventricular mass index and cardiovascular events in chronic kidney disease. <italic toggle="yes">Am. J. Med. Sci.</italic><bold>351</bold> (1), 91&#8211;96 (2016).<pub-id pub-id-type="pmid">26802763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjms.2015.10.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancia</surname><given-names>G</given-names></name><etal/></person-group><article-title>2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA)</article-title><source>J. Hypertens.</source><year>2023</year><volume>41</volume><issue>12</issue><fpage>1874</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000003480</pub-id><pub-id pub-id-type="pmid">37345492</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Mancia, G. et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). <italic toggle="yes">J. Hypertens.</italic><bold>41</bold> (12), 1874&#8211;2071 (2023).<pub-id pub-id-type="pmid">37345492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HJH.0000000000003480</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>